Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,575.56
(
-0.74%
)
US TECH 100
23,629.20
(
-0.70%
)
Dow Jones
45,809.63
(
-0.90%
)
Brent Oil
108.83
(
2.11%
)
Bitcoin
69,209.01
(
-2.85%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 77292

Tuesday, 05/05/2009 5:44:06 PM

Tuesday, May 05, 2009 5:44:06 PM

Post# of 257259
TEVA MNTA – That may be another benefit of the new formulation, but I think Teva is more concerned about a generic Copaxone in the US than they are about competition from the new oral meds.

Let me put this another way: If not for the threat of a generic, I doubt that Teva would've embarked on the program to develop a low-volume formulation.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up